MoAb to CCL5 reduces T-cell proliferation in vitro
| . | CCL5* . | CCL3† . | CCL4† . |
|---|---|---|---|
| Absolute reduction, cpm × 103 | 48.9 | −4.2 | −5.2 |
| Reduction, % | 77.7 | −13.8 | −17.1 |
| . | CCL5* . | CCL3† . | CCL4† . |
|---|---|---|---|
| Absolute reduction, cpm × 103 | 48.9 | −4.2 | −5.2 |
| Reduction, % | 77.7 | −13.8 | −17.1 |
The addition of anti-CCL5 MoAb significantly reduced allospecific proliferation of CCR1+/+ wild-type T cells in vitro compared with isotype control (P < .05), whereas anti-CCL3 and anti-CCL4 MoAb did not. Data are presented as means plus or minus SEM and are from 1 of 3 similar experiments.
Based on reference T + DC + IgG of 62.9 ± 6.1 cpm × 103.
Based on reference T + DC + IgG of 30.4 ± 1.3 cpm × 103.